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Abstract
In recent years, an increasing number ofmitochondrial disorders have been associatedwithmuta-
tions in mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs), which are key enzymes of mito-
chondrial protein synthesis. Bi-allelic functional variants in VARS2, encoding the mitochondrial
valyl tRNA-synthetase, were first reported in a patient with psychomotor delay and epilepsia par-
tialis continua associated with an oxidative phosphorylation (OXPHOS) Complex I defect, before
being described in a patient with a neonatal form of encephalocardiomyopathy. Here we provide
a detailed genetic, clinical, and biochemical description of 13 patients, from nine unrelated fam-
ilies, harboring VARS2mutations. All patients except one, who manifested with a less severe dis-
ease course, presented at birth exhibiting severe encephalomyopathy and cardiomyopathy. Fea-
tures included hypotonia, psychomotor delay, seizures, feeding difficulty, abnormal cranial MRI,
and elevated lactate. The biochemical phenotype comprised a combined Complex I and Com-
plex IV OXPHOS defect in muscle, with patient fibroblasts displaying normal OXPHOS activity.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
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Homology modeling supported the pathogenicity of VARS2 missense variants. The detailed
description of this cohort further delineates our understanding of the clinical presentation asso-
ciated with pathogenic VARS2 variants and we recommend that this gene should be considered in
early-onset mitochondrial encephalomyopathies or encephalocardiomyopathies.
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1 INTRODUCTION
Mitochondria are defined as the powerhouses of the cell, since
they produce a usable energy source, adenosine triphosphate (ATP),
through oxidative phosphorylation system (OXPHOS). This process is
carried out by themitochondrial respiratory chain (MRC), and the ATP
synthase, which are embedded in the inner mitochondrial membrane
(MIM). The MRC is composed of four multi-subunit complexes (CI to
CIV) and two mobile electron carriers (ubiquinone and cytochrome
c) that produce a proton gradient across the MIM, which is then
used by Complex V (FoF1 ATP synthase) to produce ATP [Lightowlers,
Taylor, & Turnbull, 2015; Smeitink, Zeviani, Turnbull, & Jacobs, 2006].
OXPHOS proteins are uniquely under the dual genetic control of two
genomesandas such,mitochondrial disorders canbecausedbydefects
in either the mitochondrial DNA (mtDNA) or nuclear DNA [Spinazzola
& Zeviani, 2009]. Mutations in several genes responsible for defects
of mitochondrial protein synthesis, affecting either mtDNA or nuclear
encoded genes, have been reported to cause awide range ofmitochon-
drial syndromes [Ghezzi & Zeviani, 2012; Rotig, 2011]. Mitochondrial
aminoacyl-tRNAsynthetases (mt-aaRSs) are keyenzymes inmitochon-
drial protein synthesis since they catalyze the specific attachment of
amino acids to their cognate tRNAs. Recently, an increasing number
of mitochondrial disorders have been associated with variants in mt-
aaRSs genes [Coughlin et al., 2015; Diodato et al., 2014ba,a; Konoval-
ova & Tyynismaa, 2013; Simon et al., 2015]. However, for some mt-
aaRSs (i.e., VARS2, MIM# 615917), very few individual patients have
been described and the associated phenotype is thus poorly defined.
A homozygousmissense pathogenic variant (c.1100C> T, p.Thr367Ile;
NM_001167734.1) in VARS2, the gene encoding the mitochondrial
valyl tRNA-synthetase, was described in a patient with a clinical pic-
ture characterized by psychomotor delay and epilepsia partialis con-
tinua associated with a mitochondrial Complex I defect [Diodato et al.,
2014ba,b]. Additionally, compound heterozygous variants in VARS2
(the previously reported c.1100C > T, p.Thr367Ile plus a c.601C > T,
p.Arg201Trp variant) were reported in a patient with a neonatal
form of encephalocardiomyopathy [Baertling et al., 2017]. Pathogenic
variants in VARS2 were also described in two patients included in
largewhole exome sequencing (WES) studies although detailed clinical
and/or biochemical characterization was not provided [Pronicka et al.,
2016; Taylor et al., 2014]. Herewe report a detailed clinical andmolec-
ular description of the patients (and affected siblings) reported in the
previous WES studies and describe 11 additional patients from unre-
lated families presentingwith a severe infantilemitochondrial disorder
associated with VARS2 pathogenic variants, further defining the clini-
cal and biochemical features associated with VARS2 defects.
2 MATERIALS AND METHODS
2.1 Standard protocol approvals and patient
consent
Informed consent to participate in the study was obtained from all
affected individuals or their parents in case of study participants under
the age of consent. The study was approved by the Ethical Commit-
tees of the Institutional Review Board at the Icahn School of Medicine
at Mount Sinai, New York, NY (P1 and P2), the Technische Universität
München (P3), the Neurological Institute Besta, Milan, Italy (P4), the
National Research Ethics Committee (UK) (P5), the Bioethical Com-
mission at Children's Memorial Health Institute (P6-7), the Ethical
Committee of Baylor College of Medicine, Houston, US (P8-10), and
the Ethical Review Board of Helsinki University Hospital, Helsinki,
Finland (P11-13) in agreement with the Declaration of Helsinki.
2.2 Molecular studies
P1 and P2 received clinicalWES prior to enrollment in theMount Sinai
study to further investigate mt-aaRSs disorders. WES for P1 was com-
pleted atAmbryGenetics (Viejo, CA). GenomicDNA from the proband,
mother, and father was isolated from peripheral blood samples, and
WES was completed on the family trio. DNA samples were prepared
using a SeqCap EZVCRome2.0 (RocheNimbleGen,Madison,WI, USA)
capture, and 100 base pair (bp), paired end sequencing was performed
on an Illumina, San Diego, CA, USAHiSeq 2000 instrument. Mean cov-
erage for the proband was 105.4 with 93.83% of targeted bases with
≥20× coverage. Mean coverage for the mother's sample was 102.31
with 93.56%of targeted baseswith≥20× coverage;mean coverage for
the father's samplewas 95.78with 93.6% of targeted baseswith≥20×
coverage. WES for P2 was completed at Baylor College of Medicine
Medical Genetics Laboratories (Houston, TX). Genomic DNA was pre-
pared from a peripheral blood sample. The exome capture was per-
formed using VCRome 2.1 (Roche NimbleGen,Madison,WI, USA), and
100 bp, paired-end sequencing was performed on the Illumina HiSeq
2000 platform. The quality control thresholds include mean coverage
of targetedbases>100× and>95%of targetedbases covered at>20×.
The WES also included mitochondrial genome screening. The mito-
chondrial genome was amplified by long-range PCR and subjected to
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paired-end library construction. Themean depth of coverage for mito-
chondrial sequencing was>25,000×.
WES on genomic DNA from affected individual P3 was performed
at the Institute of Human Genetics (Munich, Germany) using the Sure-
Select HumanAll Exon 50Mb kit (Agilent, Santa Clara, CA, USA) for in-
solution enrichment followed by sequencing as 75 bp paired-end runs
on a HiSeq2500 (Illumina) as described previously [Haack et al., 2012;
Kremer et al., 2016]. This achieved an average of 143-fold coverage
with 97.7% of the exome covered at least 20-fold.
P4was investigatedbya targetedNGSapproachusing a customized
gene panel (TruSeq Custom Amplicon; Illumina, San Diego, CA, USA)
containing genes associated with mitochondrial disorders, according
to the procedure recently reported [Legati et al., 2016].
P5 and P7 underwent WES analysis as previously described [Pron-
icka et al., 2016; Taylor et al., 2014].
P8 and P10 had clinical WES as previously described [Yang et al.,
2014]. Analysis of variants followed the guidelines of the American
College ofMedical Genetics and Genomics [Richards et al., 2015].
Genomic DNA of patients P11-13 was extracted using standard
protocols. P12 underwent clinical WES as previously described [Bas-
taki et al., 2016].
All the novel sequence variants identified in VARS2 have been sub-
mitted to a public database (https://www.lovd.nl/VARS2).
2.3 Histopathological studies
Quadriceps muscle biopsies were obtained from subjects P2, P3, P4,
P5, and P6. Transversely orientated, frozen muscle sections (10 𝜇m)
were subjected to standard histological and histochemical procedures
including sequential cytochrome c oxidase (COX)/succinate dehydro-
genase (SDH) histochemistry. Electron microscopy of P2 muscle was
performed according to standard procedures.
2.4 Biochemical studies
MRC complex activities were measured using standard spectropho-
tometric methods [17] in muscle homogenate of P2, P3, P4, P5, and
P6, and digitonin-treated skin fibroblasts of P4, P5, and P7; complex
activities were then normalized to citrate synthase activity, an index of
mitochondrial content in the analyzed specimens [Bugiani et al., 2004;
Kirby, Thorburn, Turnbull, & Taylor, 2007].
2.5 De novometabolic labeling of mitochondrial
encoded proteins
Mitochondrial protein synthesis in P5 cultured cells was performed
as previously described [Bruni, Gramegna, Oliveira, Lightowlers, &
Chrzanowska-Lightowlers, 2013]. Briefly, fibroblasts were washed
twice in methionine/cysteine-free DMEM (Sigma, St. Louis, MO,
USA). After addition of 0.1 mg/ml emetine, cells were pulsed with
[35S] methionine/cysteine (PerkinElmer, Waltham, MA, USA) for 1 hr.
Aliquots (50 𝜇g) of total cell proteinwere separated by 15% (w/v) SDS-
PAGE and signals were detected using the Typhoon FLA 9500 Phos-
phorImager and ImageQuant software (GE Healthcare Life Sciences,
Pittsburgh, PA, USA).
2.6 Immunoblotting
Lymphoblast samples from P1 and two control lines (C1 and C2) were
processed for immunoblotting as previously described [Webb et al.,
2015]. The membrane was probed with mouse anti-OXPHOS cocktail
at 1:1,000 (MitoSciences, ab110411, Eugene, OR, USA) and with rab-
bit anti-GAPDH at 1:5,000 (Sigma, G9545, St. Louis, MO, USA) used as
a loading control. Antibodies were visualized using IRDye 800CW or
IRDye 680RD secondary antibodies and theOdyssey Infrared Imaging
System (LI-CORBiosciences, Lincoln, NE, USA).
Total protein was extracted from fibroblasts and muscle tissue of
P5 and fibroblasts of P4, separated on 12% SDS-PAGE gels, trans-
ferred to PVDF membranes and analyzed by immunoblotting using
primary antibodies to VARS2 (either custom-made or from Mito-
Sciences, Eugene,OR,USA),NDUFB8,MTCOI,MTCOII, COXIV, SDHA,
UQCRC2, ATP5A, and VDAC (all from Abcam, Cambridge, UK). 𝛽-
actin (Sigma, G9545, St. Louis, MO, USA), GAPDH (Millipore, Burling-
ton, MA, USA), and 𝛼-tubulin (Abcam) were used as loading controls.
Chemiluminescent signals were detected using the Amersham ECL
Prime Kit (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and the
ChemiDocTMMP Imaging System (Bio-Rad, Hercules, CA, USA).
2.7 Homologymodeling
Homology modeling of the mitochondrial human Valine-tRNA ligase
(VARS2, NCBI: NP_001161206.1) in the amino acid interval 130–
1,086 was made employing as the template the Protein Data Bank
(PDB) structure 1IVS (representing the Valine-tRNA ligase from Ther-
mus thermophilus, which shares 37% amino acid identity with human
VARS2). All side chain atoms in the template structure were deleted.
Then, the residues of this backbone-only structure were renamed and
renumbered (in PDB format) to the corresponding amino acids in the
human VARS2 according to the pairwise sequence alignment shown in
the Supp. File S1. All side chainswere re-built and amino acid insertions
added using MODELLER (v. 9v17) [Sali et al., 1993] without allowing
changes in the model backbone conformation relative to the template
structure. The cognate tRNAVal molecule and the Val-AMP analogue
N-[L-valyl]-N’-adenosyldiaminosulfone (Val-AMS) co-crystallized with
the template protein were added to the VARS2 model maintaining
their binding poses. Finally, the full amino acids of insertions and flank-
ing residues, and the side chains of the remainder of the protein, were
energyminimizedwith the Dreiding force field.
Sequence logos were calculated on the VARS2 multiple sequence
alignment asdisplayed in theMiSynPatdatabase (misynpat.org) includ-
ing all organisms. Sequence logos were generated using WebLogo
[Crooks, Hon, Chandonia, & Brenner, 2004].
3 RESULTS
3.1 Case reports
A short clinical description of the patients with biallelicVARS2 variants
is reported below; pedigrees are shown in Figure 1, whereas the main
clinical and laboratory findings are reported in Table 1.
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F IGURE 1 Pedigrees. Pedigrees of the nine families are shown documenting the segregation of alleles
P1 is a 5-year-old female of Polish ancestry born at 38 weeks ges-
tation by normal vaginal delivery (family 1; Figure 1). Family history is
notable for consanguinity; parents are second cousins. She presented
with hypotonia and poor suck from birth, followed by developmental
delay, poor coordination, dystonic movements and ataxia. At 3.5 years,
she was unable to sit, crawl, or walk and her language was limited to
fewer than 30 words. At 3 years and 8 months, she presented with
seizures, which included generalized tonic-clonic, focal, and myoclonic
types. MRI completed at 11.4 months of age was unrevealing; there
were no acute intracranial findings or abnormalities of the orbits or
brainstem identified. Evaluation of the parenchyma was limited due
to incomplete myelination at this age; the myelination pattern was
read as within normal limits for age. The second MRI, performed at
3 years and 6 months of age, revealed T2/FLAIR hyperintensity in the
periventricular white matter and cerebellar hemispheres bilaterally,
and diffuse cerebral volume loss. MR spectroscopy showed a small
doublet peak at 1.3 ppm in voxels over the left parietal white matter
and frontal horns, suggesting lactate. An additional MRI, performed
at 4 years 9 months revealed more advanced ill-defined prominent
T2/FLAIR hyperintensity in the periventricular white matter as well
as multifocal areas of abnormal T2/FLAIR hyperintensity in the cortex
and subcortical white matter.
P2was a Caucasian female born at 39weeks gestation by Cesarean
section due to breech presentation (family 2; Figure 1). Apgar scores
were 7 and 9 at 1 and 5 min, respectively. Shortly after birth, the new-
bornwas transferred to the neonatal intensive care unit for evaluation
of stridor. Nasal endoscopy revealed bilateral vocal cord paresis, and
the patient was diagnosed with central and obstructive sleep apnea.
A tracheostomy was performed for airway protection at 2 months
of age. Other symptoms/signs were hypotonia, hyporeflexia, exagger-
ated startle, staring episodes, and congenital hip dislocation. Echocar-
diogram completed at 2 months of age revealed moderate to severe
biventricular hypertrophy with normal ventricular function and mod-
erate pericardial effusion. Dysmorphic features noted on examina-
tion included microcephaly (occipitofrontal circumference [OFC] on
2nd centile), a round, full face, prominent eyes with shallow orbits, a
small nose with flat nasal root, a small mouth with down-turned cor-
ners,micrognathia, and inverted nipples. Initial brainMRI completed at
12 days of age was unremarkable, but a second brain MRI performed
at 3 months revealed moderate to severe diffuse cerebral and cere-
bellar atrophy, scattered areas of cortical restricted diffusion, most
pronounced around the Sylvian fissures bilaterally, as well as sub-
tle thalamic restricted diffusion bilaterally. MR spectra showed large
lactate peaks in the deep gray matter and in the subcortical white
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matter of the left cerebral hemisphere. The patient died at 3.5 months
of age.
P3 was the son of a non-consanguineous Jewish couple, born at
36 weeks by spontaneous delivery (family 3; Figure 1). Apgar scores
were 7 and 8 at 1 and 5 min, respectively. He presented at birth with
severe stridor, difficulty in sucking, dysmorphic features, hypertonia
of the lower limbs. Echocardiography revealed hypertrophic cardiomy-
opathy and severe pulmonary hypertension. Laryngoscopy and bron-
choscopy revealed laryngomalacia. The cranium was asymmetric with
an OFC of 32 cm. Over the 1st year of life, progressive microcephaly
developed due to craniosynostosis (since the age of 5months the OFC
remained at 40 cm). At age 11 months he underwent surgical correc-
tion of craniosynostosis. The stridor, cardiomyopathy and pulmonary
hypertension improved over the first year of life. However, he contin-
ued to feature hypertonia and developmental delay. BrainMRIwas not
performed. At 19months, he died suddenly at home during sleep.
P4was the second child of healthy, unrelated parents of Italian ori-
gin. Family history was unremarkable (family 4; Figure 1). She was
born at term following a pregnancy complicated by IUGR in the third
trimester; at birth, weight, length, and OFC were on the 3rd centile,
Apgar scores were 8 and 9 at 1 and 5 min, respectively. From the first
months of life, hypotonia, feeding difficulty and psychomotor delay
were reported. She first came to clinical attention at 3 months of age
when she suffered from epileptic seizures. Neurological examination
showed reduced voluntarymovements, no postural control and hyper-
tonia. EEG revealed diffuse abnormalities with poorly organized cere-
bral rhythms and epileptiform seizure activity. Clobazam and clon-
azepam treatment was started without obvious benefit. Hypertrophic
cardiomyopathy was detected. Cranial MRI revealed hypoplasia of the
cerebellum and corpus callosum. A mitochondrial disease was sus-
pected and the patientwas referred to our Institute at 4months of age.
Clinical examination showed poor somatic growth and microcephaly
(OFC < 3rd centile) and a severe neurological impairment, character-
ized by absence of head control, response to sounds and language,
poor eye contact, hyperreflexia, and hypertonia. Visual evoked poten-
tial showed central conduction abnormalities, fundus oculiwas normal.
The child died at 5months, because of cardiac arrest.
P5 was born by normal vaginal delivery, at full term (family 5;
Figure 1). He was a floppy infant and his clinical history was character-
ized by psychomotor delay, ptosis and ophthalmoparesis, dysarthria,
and dyspraxia. He subsequently developed generalized epileptic
seizures that responded favorably to levetiracetam and a slowly pro-
gressive fatigue and exercise intolerance. The last neurological exam-
ination at 18 years showed restricted range of eye movements in all
directionswith some sparing of downgaze; bilateral ptosis; generalized
hypotonia as well as facial, proximal limb and axial weakness. Cranial
MRI andCTdemonstrated symmetrical bilateral basal ganglia calcifica-
tion. In addition, the cranialMRI also revealed a symmetrical increased
T2 signal in the peri-trigonal white matter (Figure 2). Recent echocar-
diography has revealed mild concentric ventricular hypertrophy. An
older sister died at the age of 21months following pneumonia. Shewas
also floppy and had restricted eye movements with bilateral ptosis. A
diagnosis of congenital myasthenia had been considered but she died
before this could be definitively investigated.
P6was born at term by spontaneous delivery fromPolish unrelated
parents with a positive genetic history (family 6; Figure 1). Their
older daughter presented at birth with hypotonia, laryngeal stridor,
respiratory failure, he rapidly developed hypertrophic cardiomyopa-
thy, impaired contractility and died at age of 32 following a cardiac
arrest; massive cardiac hypertrophy and fatty liver accumulation were
found at autopsy (family 6; Figure 1). The birth weight of P6 was
3,420 g and Apgar score was 10 at 1 min. Fetal and postnatal ECHO
was normal. From birth the boy presented with stridor, hypotonia,
and respiratory failure, which required mechanical ventilation for
3 weeks. Stridor was still present after extubation but no anatomic
abnormality was revealed by two laryngoscopic examinations. Dur-
ing the follow-up, general clinical condition remained poor and
characterized by generalized hypotonia, lack of swallowing reflex,
tachycardia, and gallop cardiac rhythm. At 23 days of age, cardiac
ultrasound revealed hypertrophy of left ventricle and interventricular
septum. Neurological examination revealed poor reactivity with lack
of response to visual and auditory stimuli, axial hypotonia, and limb
spasticity. The heart size increased rapidly in three consecutive chest
radiographs at 20, 50, and 78 days of life. The boy died at 3 months of
age.
P7, the younger brother of P6 (family 6; Figure 1), was born at term
with a body weight of 3,170 g, and Apgar score was 10 at minute
1. Soon after birth he presented with stridor and developed respira-
tory failure, which required artificial ventilation. Increasingmyocardial
hypertrophy was observed in three consecutive cardiac ultrasounds.
Neurological examination showed poor reactivity, poor facial expres-
sion and squint, axial hypotonia with limb spasticity. Hearing exam-
ination was normal and ophthalmic fundus unchanged. Head ultra-
sound did not show any abnormalities. His global clinical condition
gradually improved and at 34 days of age the cardiorespiratory pic-
ture was stable; the boy was discharged after 2 months of hospitaliza-
tion. At 7 months of follow-up, the boy showed psychomotor retarda-
tion and episodes of increasedmuscle tone. Intermittent recurrence of
stridor with respiratory difficulty continued. EMG was normal. Brain
MRI performed at the age of 8 months showed hypoplasia of the ver-
mis,mild cerebral atrophyandsmall symmetricT2/FLAIRhyperintense
changes in thalamus and septum pellucidum. Since pathological dis-
charges were observed on video-EEG, symptomatic epilepsy was diag-
nosed and antiepileptic drugs were administered with good response.
At the age of 10 months, he was fully gastrostomy fed. At 4 years
the boy had developed chronic respiratory failure and a tracheostomy
was performed. Cryptorchidism and chronic pancreatitis were also
reported. The patient died at the age of 9 years during an episode of
central apnea.
P8 was a male born to healthy parents of Mexican ancestry (fam-
ily 7; Figure 1). Pregnancy was uncomplicated and resulted in spon-
taneous delivery at term. The patient presented with hypotonia and
poor sucking at birth. Respiratory failure followed soon after birth
and ultrasound revealed hypertrophic cardiomyopathy with biven-
tricular dilation and thickening of the ventricular walls, as well as
hepatosplenomegaly. The child suffered a severe metabolic acidosis
including high plasma lactate and died on the ninth day of life.P9was a
female full-sibling to P8, born after her brother's death, whose clinical
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F IGURE 2 MRI: Sagittal T1 (A and D), coronal T2 (B and E), and axial flair (C and F) images of P11, age 2 years and 4 months, and P12, age
13 months, showing cerebellar atrophy, thinning of the posterior corpus callosum (red/dark arrows), signal intensity in dentate nuclei and patho-
logical signal in the lateral parts of thalami that look smaller (yellow/light arrows). G and H: Axial flair images of P5, age 15 years: yellow arrows
indicate diffuse symmetrical periventricular white matter abnormality; red arrows indicate basal ganglia calcification
course was remarkably similar and died at 3 months of age (family 7;
Figure 1).
P10 was a male born following an uncomplicated pregnancy to
healthy parents ofMexican descent (family 8; Figure 1). The child expe-
rienced hypotonia of all limbs and feeding difficulties frombirth. Respi-
ratory distress also occurred in the first few days of life and the child
was found to have hypertrophic cardiomyopathy. Seizures began in the
first month of life and continued despite treatment with antiepilep-
tic drugs. The patient also experienced severe metabolic acidosis with
persistently increased lactate and was noted to have a single anuric
kidney.
P11 was the first child of a consanguineous healthy couple of
Afghan origin (family 9; Figure 1). She was born at term (birth weight
3,300g, length51 cm), andhadnoneonatal problems. Shewas referred
for investigations at the age of 6 months because of poor head con-
trol. On examination, she was noted to be hypotonic, microcephalic,
and developmentally delayed. Nystagmus was noticed by the age of
1 year and at the age of 1 year 3 months a brain MRI showed cere-
bellar atrophy, slight thinning of the posterior corpus callosum and
pathological FLAIR hyperintense signal in the thalami. At the age of
2 years, when her epileptic seizures started, she was able to say a
few words and turn over, but never learned to crawl. She developed
intractable multifocal epilepsy with prolonged seizures. A repeat MRI
at the age of 2 years 4 months showed progression of the cerebel-
lar atrophy, involving both cerebellar hemispheres and vermis, and
FLAIR/T2 hyperintense signal in dentate nuclei and thalami (Figure 2).
Her disease progressed with regression of skills and feeding difficul-
ties evident by the age of 4 years. She died of pneumonia at the age of
7 years.
P12, sister of patient 11, the second child of the family, was a term
baby (birth weight 3,450 g/length 49 cm/OFC 35 cm, Apgar score 9 at
1 min) (family 9; Figure 1). At the age of 6 months, when first inves-
tigated for delayed motor development, she was hypotonic with poor
head control and microcephaly (−2 SD). Brain MRI at the age of 1 year
1 month showed cerebellar atrophy and slightly thinning of the poste-
rior corpus callosum (Figure 2). A 1H-MRS from the thalamus showed
no lactate peak and EEG showed no epileptiform discharges. Epileptic
seizures started with status epilepticus at the age of 2 years 1 month
and EEG revealed multifocal spikes, spike-slow waves and general dis-
turbance. At that age she was alert, able to say few words, able to roll
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over and catch toys. By the age of 4 years her disease had progressed,
skills had regressed, she had developed limb spasticity and needed a
gastrostomy for feeding. Epilepsywas intractable. She died of pneumo-
nia at the age of 8 years.
P13, brother of patients 11 and 12, the third child of the family, was
diagnosed with VARS2 mutations antenatally (family 9; Figure 1). He
was born at term (birth weight 3,810 g, length 52.5 cm/OFC 34.0 cm
(−1 SD), Apgar score 9 at 1 min). Neonatal brain MRI showed uni-
lateral cerebellar hypoplasia. No neonatal problems were noticed. At
5 months of age, his head growth was slowed to −3 SD and he was
hypotonic without any signs of cardiomyopathy in heart ultrasound.
3.2 Morphological studies
Histochemistry of P3 and P4 muscle samples was normal, whereas
mild, unspecific myopathic changes in P5 and signs of neurogenic
atrophy in P6 were reported (not shown). In P5, COX-deficient/SDH-
positive fibers were evident (not shown).
Electron microscopy of P2 muscle disclosed relatively normal
myofibrillar architecture, myofiber nuclei, sarcolemmal membranes,
and basement membranes; there was abnormal/excessive accumula-
tion of glycogen (non-membrane-bound) both intermyofibrillary and
especially subsarcolemmal, which has a variably granular appearance
to very focally filamentous appearance. The mitochondria appeared
relatively decreased in number (sparse overall) and size, with mostly
unremarkable morphology although some are distorted or atypical
(with atypical cristae) (not shown).
3.3 Autopsy findings
For P2, post-mortem examination of the heart revealed severe biven-
tricular hypertrophy and mildly asymmetrical hypertrophy of the ven-
tricular septum; microscopic sections showed prominent and dif-
fuse myocyte vacuolar degeneration. Neuropathological evaluation
revealed a subacute and acute necrotizing encephalopathy consistent
with Leigh syndrome with lesions evident in the thalamus and cor-
tex, having typical histopathology of vacuolated neuropil with gliosis
and prominent vasculature. Cerebellar cortical degeneration was also
noted; the substantia nigra appeared relatively spared (not shown).
In P6, post-mortem examination showed hydrothorax and
hydropericardium, and left ventricle hypertrophy with immature
cardiac cells.
3.4 Biochemical studies
The activities of all theMRCcomplexeswerewithin control range inP5
andP7 fibroblasts,whereas apartial reductionofCIV/CS (69%ofmean
control value) was observed in P4 fibroblasts. In these cells respiratory
capacity, assessed by Seahorse micro-scale oxygraphy, was normal in
standard, glucose medium but was decreased in galactose-medium, a
condition that forces cells to useOXPHOS to produce ATP rather than
glycolysis (Figure 3A).
MRC complex activities in muscle samples disclosed a combined CI
and CIV reduction in P5 (60% of mean control values), a CIV reduction
in P3 (17% of mean control) and P6 (25% of mean control), whereas
were normal in P2 and P4muscles.
3.5 WES and Sanger validation
Details of the identifiedVARS2variants areprovided inTable2.All vari-
ants are numbered according to NM_001167734 reference sequence.
A homozygous, reported pathogenic, c.1100C > T (p.T367I) VARS2
variant (ClinVar: RCV000129937.4) was detected in P1. Both parents
were heterozygous for this variant. In P2 compound heterozygous
VARS2 variants, c.2556-2A > G and c.1100C > T (p.T367I), were iden-
tified. Sanger sequencing confirmed the proband to be heterozygous
for both variants, and identified themother to be heterozygous for the
c.1100C> T variant and the father to be heterozygous for the c.2556-
2A>G variant.
In P3 after excluding previously annotated single nucleotide
changes occurring with high frequency in the population, prioritiz-
ing homozygous or compound heterozygous variants with functional
impact (i.e., non-synonymous variants and changes affecting splice
sites) as expected for a recessively inherited trait, WES identified two
compound heterozygous variants in VARS2: c.1546G > T (p.Glu516*)
and 2239G>A (p.Ala747Thr).
After filtering procedure similar toWES (frequency threshold>1%)
in P4 we identified two variants in VARS2: c.1100C > T (p.Thr367Ile)
and c.1150G > A (p.Asp384Asn). The analysis of the single NGS reads
revealed that the twovariants are present ondifferent alleles, confirm-
ing the compound heterozygous state of the patient. Sanger sequence
confirmed the presence of the variants.
In P5 and P7, VARS2 mutations were identified by WES and
confirmed by Sanger sequencing as previously described [Pronicka
et al., 2016; Taylor et al., 2014]. P5 was found heterozygous for the
c.1135G > A (p.Ala379Thr) and c.1877C > A (p.Ala626Asp) muta-
tions whereas P7 resulted compound heterozygous for c.1100C > T
(p.Thr367Ile) and c.1490G>A (p.Arg497His).
In P6, older affected brother of P7, the same p.Thr367Ile and
p.Arg497His mutations were identified by Sanger sequencing.
Clinical WES was conducted on P8, which reported the child was
homozygous for c.1258G > A (p.Ala420Thr). Sanger sequencing con-
firmed the presence of the mutation in the child and in the proband's
sibling P9, aswell as the heterozygous state of the parents. Patient P10
also e clinical WES: although he was reported to be unrelated to fam-
ily of P8-P9, the same homozygous c.1258G>A (p.Ala420Thr) variant
was identified.
Clinical WES was also conducted on P12, and it detected the same
homozygous c.1100C > T (p.Thr367Ile) variant in VARS2 as in P1.
Sanger sequencing confirmed the presence of the mutation in the
proband and in her affected siblings (P11 and P13), aswell as their par-
ents’ heterozygosity.
3.6 Functional studies
In order to assess the effect of the identified VARS2 variants on pro-
tein levels, immunoblotting was performed using available patient
samples (P1 lymphoblasts, P4 fibroblasts, and P5 muscle). NDUFB8
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F IGURE 3 Functional studies. A: Micro-oxygraphy performed in P4 and control fibroblasts cultured in galactose medium. Y-axis values corre-
spond to themaximal respiration rate, expressed as pMolesO2/min/cell. Data are represented asmean± SD. Two-tail, paired t-test was applied for
statistical significance (***P< 0.001). B: Western blot analysis of P1 lymphoblasts using anti-OXPHOS cocktail (ATP5A, UQCRC2, SDHB,MTCOII,
NDUFB8) and anti-GAPDHantibodies.C:Western blot analysis of P4 fibroblasts using antibodies against VARS2,mitochondrial encodedComplex
IV subunit 1 (MTCOI), Complex II subunit A (SDHA), and GAPDH, the latter being used as a loading control.D: Western blot analysis of P5 muscle
sample using antibodies against VARS2, Complex I subunit (NDUFB8), Complex II subunit (SDHA), Complex III core protein II (UQCRC2), Complex
IV subunits (MTCOI,MTCOII), ComplexV subunit (ATP5A) and alpha-tubulin, the latter being used as a loading control. E: De novometabolic label-
ing inP5 and control fibroblasts. Separatedon15%PAAgel. Coomassie blue stain as loading control.F:Western blot analysis of P5 fibroblasts using
antibodies against VARS2, NDUFB8, Complex IV subunits (MTCOII, COXIV), VDAC and beta-actin, the last two being used as loading controls
and MTCOII protein levels were reduced in P1 lymphoblasts com-
pared with control samples (Figure 3B). A decrease in steady state
level of VARS2 protein was observed in P4 fibroblasts compared
with control lines (Figure 3C); furthermore, a reduction in MTCOI
levels was present in P4, whereas SDHA levels were unaffected
(Figure 3C). P5 muscle showed normal VARS2 steady state lev-
els but decreased amounts of Complex I (NDUFB8) and Complex
IV (MTCOI and MTCOII) subunits compared with a control muscle
(Figure 3D).
Next we determined the consequence of the VARS2 mutations on
mitochondrial translation by performing de novo metabolic labeling in
patient and control fibroblasts. Data analysis in P5 fibroblasts com-
pared with aged-matched control cells indicated that mutant VARS2
caused no significant changes in the rate of mitochondrial trans-
lation (Figure 3E). Immunoblotting analysis was performed on the
same fibroblasts and also showed no differences in VARS2 levels or
steady-state levels of Complexes I and IV subunit (Figure 3F), consis-
tent with the normal mitochondrial protein synthesis and reports of
other mutated mitochondrial aa-tRNA synthetases, where the conse-
quential biochemical defect is usually expressed in muscle but not in
cultured fibroblasts [Almalki et al., 2014].
4 DISCUSSION
Mitochondrial diseases due to defects in mt-aaRS are emerging as
an important category of mitochondrial disorders. Despite report-
ing of a strict genotype–phenotype association for many mt-aaRS, in
some cases mutations in the same gene have been associated with
very different clinical phenotypes; for example, pathogenic variants
in AARS2 (encoding for alanyl-tRNA synthetase) are associated either
with infantile mitochondrial cardiomyopathy [Götz et al., 2011] or
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leukodystrophy with ovarian failure [Dallabona et al., 2014]. Other
examples are the different clinical phenotypes caused by FARS2
[Almalki et al., 2014; Elo et al., 2012], LARS2 mutations [Pierce et al.,
2013; Riley et al., 2016], orMARS2mutations [Bayat et al., 2012;Webb
et al., 2015]. It remains poorly understood why genetic defects in mt-
aaRSs that are ubiquitous enzymes involved in mitochondrial trans-
lation, can cause such different phenotypes in which specific tissues
or organs are affected. Different hypotheses have been postulated to
explain this variability, taking into account the tissue-related amino
acid concentrations, the different cell susceptibility to impaired mito-
chondrial protein synthesis, variable protein turnover in different tis-
sues or the multiple and still unknown functions of mt-aaRSs. For
this reason, describing the phenotype related to a specific mt-aaRSs
becomes both important as well as intriguing.
Recently, Baertling et al. (2017) reported a patient harboring
compound heterozygous pathogenic VARS2 variants presenting with
neonatal encephalocardiomyopathy. Here we describe the clinical and
biochemical features of 13 additionalVARS2 patients from 9 unrelated
families (Table1, Supp. Tables S1, andS2). Almost all patients presented
with a phenotype characterized by severe early-onset encephalopa-
thy with hypotonia, stridor and respiratory failure. Hypertrophic car-
diomyopathy is a common feature of this disorder, although it was
absent in P1 who presented with the severe, early-onset clinical pic-
ture described in the other patients. Cardiomyopathy was not investi-
gated in P11 or P12. P11 and P12 presented a severe encephalopathy
with refractory epilepsy, dying at 7 and 8 years, respectively, whereas
P13, whose molecular diagnosis was detected antenatally, had ele-
vated lactate andminor changes at brainMRI already at birth, showed
slowed head growth and hypotonia, but was otherwise symptom-free
at 5 months of age. P1 and P13 harbored the same homozygous
VARS2 variant, and do not present cardiomyopathy; the first patient
reported by Diodato et al. (2014a,b), homozygous for the same vari-
ant, did not present cardiomyopathy either. These data could sug-
gest that the c.1100C > T (p.Thr367Ile) variant could have a lesser
effect to the heart. Epilepsy seems to be a common feature of VARS2-
related mitochondrial disease, configuring clinical pictures of vari-
able severity (Supp. Table S2). Seizures appeared later in life in the
other patient described with a long survival (P7). P5 presented a less
severe course characterized by developmental delay, epilepsy, pto-
sis, ophthalmoparesis and myopathy. In P5 a mild concentric ventric-
ular hypertrophy was discovered in his late teens. In our cohort there
was no significant or specific involvement of other organs, apart from
kidney reflux reported in P1, anuric kidney in P10, cryptorchidism
and recurrent pancreatitis described in P7, and hepatosplenomegaly
in P8 and P9. Interestingly, recurrent pancreatitis has been recently
described in a patient with another defect of mitochondrial protein
synthesis, namely recessive mutations in RMND1, which codes for a
protein involved in mitochondrial translation (Required for Meiotic
Nuclear Division 1, S. cerevisiae homolog, MIM# 614917) [Ng et al.,
2016]. Nevertheless, we cannot exclude a possible role of antiepilep-
tic drugs in determining the recurrent pancreatitis. Lactic acidosis,
where assessed, is a common feature. Notably, pulmonary hyperten-
sion, described in P3, was described in patients harboring TMEM70
(MIM# 612418) pathogenic variants [Catteruccia et al., 2014]. MRI
patterns were rather non-specific, showing variable cerebral and
cerebellar atrophy, white matter abnormalities and basal ganglia
involvement; corpus callosum hypotrophy, frequently seen in mito-
chondrial disorders, was described in the patients reported byDiodato
et al. (2014ba,b) and recently by Baertling et al. (2017).
The biochemical phenotype is mainly represented by a combined
defect in muscle, as in P3, P5, and P6, and almost always normal in
fibroblasts. Interestingly, P4 showed a partial Complex IV defect in
fibroblasts, whereas biochemical analyses were normal in muscle. WB
analyses performed in P4 fibroblasts and P5muscle confirmed the bio-
chemical results. Additionally, decreased protein levels for NDUFB8,
representing Complex I, and MTCOII, representing Complex IV, were
noted in P1 lymphoblasts. Overall, our cohort strengthens and devel-
ops the previous biochemical description of VARS2 patients [Diodato
et al., 2014ba,b; Taylor et al., 2014], and the biochemical phenotype
caused by mt-aaRS mutations [Diodato et al., 2014ba,b], which is fre-
quently normal in fibroblasts cell lines.
The mutant VARS2 allele c.1100C > T (NM 001167734.1) is recur-
rent in our population, either in homozygosity (P1; P11-P13) or in com-
pound heterozygosity (P2, P4, P5, P6-7). The c.1100C > T allele was
present in homozygosity in the first patient of Italian ancestry [Diodato
et al., 2014ba,b], and was also present in a Greek patient [Baertling
et al., 2017]. In the present cohort, P1, P6, P7 patients are Polish, P11-
P13 are Afghan, whereas P4 is Italian. The absence of a shared ethnic
origin suggests either different independent events or a very ancient
common founder. The VARS2 variant c.1258G > A was observed in
three patients from two independent families of Mexican origin. All
three patients were homozygous for this allele, despite no reports of
consanguinity in the families. The allele has a frequency of 0.2 % in the
ExAC Latino population, which is the highest allele frequency among
the mutations reported here. This allele is reported in 0.01% of ExAC
Europeans but is not reported in African or Asian ExAC populations
and as such may represent an allele that has expanded in the Latino
population.
Five out of the six missense mutations affect residues located
in regions important for the interaction of VARS2 with the cog-
nate tRNA (p.Thr367Ile, p.Ala379Thr, p.Asp384Asn, p.Ala420Thr, and
p.Ala747Thr) (Figure 4). Crucially, most of these mutations involve
residues that are highly conserved among phylogenetically distant
organisms (Ala420 presents valine or cysteine as alternative residues
implying that this site requires conserved hydrophobicity) (Figure 4B
and Suppl. Figure S2). This underscores the functional importance of
these sites, allowing us to suggest, as a common pathogenic conse-
quence of the above non-conserved amino acid replacements, a defec-
tive binding of tRNA.
The p.Arg497His and p.Ala626Asp mutations fall near the bind-
ing pocket of the cognate valine. The first causes the replacement
of an invariant arginine with a histidine that can also acquire a posi-
tive charge through protonation but presenting much lower pKa than
the protonated arginine and thus the latter has stronger capability
to maintain a positive charge also inside the protein environment.
In addition, the rigid aromatic ring of the histidine side chain does
not reproduce the interactions of the flexible side chain of the native
arginine. Although the site of the Ala626Asp mutation is apparently
576 BRUNI ET AL.
F IGURE 4 Scheme and molecular model of VARS2 protein. A: schematic view of VARS2 protein. All the mutations reported here fall in
the tRNA synthetase domain. B: VARS2 sequence alignment among representative eukaryotes (H. sapiens, NM_001167734.1; M. musculus,
NM_175137.4; C. picta bellii, XM_008176875.1; I. punctatus, XM_017481440.1; H. saltator, XM_011150470.1; C. cinctus, XM_015730429.1; C.
annuum, XM_016687220.1; P. x bretschneideri, XM_009342992.2) around the sites of the missense mutations discussed in the text (Thr367Ile,
Ala379Thr, Asp384Asn, Ala420Thr, Arg497His, Ala626Asp, Ala747Thr). Residues that are invariant in this group of eukaryotes are shown in gray.
C: homology model of VARS2. VARS2 protein (ribbons in different colors for the various functional regions), the residues affected by the missense
mutations (yellow spheres), the bound cognate tRNA (tRNA-Val, light green ribbons and sticks), and the Val-AMP analogue (Val-AMS, magenta
sticks) are shown.Thepathogenicmechanismof thesemutations canbe inferred fromtheir location: Thr367Ile,Ala379Thr,Asp384Asn,Ala420Thr,
and Ala747Thr occur at protein sites relevant for the binding of the tRNAmolecule, whereas the Arg497His and Ala626Asp mutations affect the
binding pocket of the cognate valine
not highly conserved, the alternative residues found in other organ-
isms are either hydrophobic or serine or threonine: in contrast with
aspartic acid, all these amino acids contain aliphatic portions that
can preserve the local multiple interactions as engaged by Ala626
(Suppl. Figure S3). Furthermore, in the alignment (Figure 4B and Suppl.
Figure S2), this site never hosts a negatively charged residue like that
introduced with the Ala626Asp replacement. This can be understood
considering that such variant would cause salt-bridge shuffling, owing
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to its proximity to the ionic pairArg274-Asp635.Basedon theseobser-
vations, Arg497His and Ala626Asp mutations are both expected to
modify the conformationof thevalinebinding regionand thus to impair
enzyme function.
5 CONCLUSIONS
Herewedescribe the clinical andbiochemical phenotypeof13patients
harboring bi-allelic pathogenic VARS2 variants. The common pheno-
type is characterized by a severe, early onset cardioencephalomy-
opathy associated with a combined OXPHOS defect in muscle. The
brainMRI did not show any characteristic recognizable pattern across
patients. Patient P1 has no evidence of cardiomyopathy; she and P5
(mild, later onset cardiomyopathy) are the only subjects who remain
alive at ages 5 and 18 years, respectively. It is reasonable to infer
from our cohort's data that a poor prognosis seems to correlate with
the severity of cardiomyopathy/myopathy. P11 and P12, in which car-
diomyopathywasnot investigated, presenteda severeencephalopathy
with refractory epilepsy and died at 7 and 8 years, respectively. Indeed
patient P5 also had a relativelymild neurological phenotype. These last
observations are in linewith the extreme clinical variability ofmt-aaRS
associated phenotypes, even though the described VARS2-associated
phenotype looks rather homogenous. Structural and functional analy-
ses clearly support the pathogenic role of the identified variants. The
series of patients described here, reinforces previous findings and fur-
ther delineates the range of clinical observations caused by mutations
in VARS2, which should be investigated in early-onset mitochondrial
encephalomyopathies or encephalocardiomyopathies.
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